Newlink's phase III patient picks, antibody levels IMPRESS
CHICAGO With immuno-oncology all the rage, especially against melanoma, at the 50th annual meeting of American Society of Clinical Oncology, the pairing of potential new compounds with ipilimumab (Yervoy, Bristol-Myers Squibb Co.) proved a popular ploy.
Checkpoint inhibitors are in the game.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter